Systematic Isolation and Structure Elucidation of Urinary Metabolites Optimized for the Analytical-Scale Molecular Profiling Laboratory.


Journal

Analytical chemistry
ISSN: 1520-6882
Titre abrégé: Anal Chem
Pays: United States
ID NLM: 0370536

Informations de publication

Date de publication:
16 07 2019
Historique:
pubmed: 13 6 2019
medline: 25 9 2020
entrez: 13 6 2019
Statut: ppublish

Résumé

Annotation and identification of metabolite biomarkers is critical for their biological interpretation in metabolic phenotyping studies, presenting a significant bottleneck in the successful implementation of untargeted metabolomics. Here, a systematic multistep protocol was developed for the purification and de novo structural elucidation of urinary metabolites. The protocol is most suited for instances where structure elucidation and metabolite annotation are critical for the downstream biological interpretation of metabolic phenotyping studies. First, a bulk urine pool was desalted using ion-exchange resins enabling large-scale fractionation using precise iterations of analytical scale chromatography. Primary urine fractions were collected and assembled into a "fraction bank" suitable for long-term laboratory storage. Secondary and tertiary fractionations exploited differences in selectivity across a range of reversed-phase chemistries, achieving the purification of metabolites of interest yielding an amount of material suitable for chemical characterization. To exemplify the application of the systematic workflow in a diverse set of cases, four metabolites with a range of physicochemical properties were selected and purified from urine and subjected to chemical formula and structure elucidation by respective magnetic resonance mass spectrometry (MRMS) and NMR analyses. Their structures were fully assigned as tetrahydropentoxyline, indole-3-acetic-acid-

Identifiants

pubmed: 31188566
doi: 10.1021/acs.analchem.9b00241
pmc: PMC6666900
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

8873-8882

Subventions

Organisme : Medical Research Council
ID : MC_PC_12025
Pays : United Kingdom

Références

Rapid Commun Mass Spectrom. 1999;13(5):456-63
pubmed: 10209877
J Am Soc Mass Spectrom. 2003 Mar;14(3):265-77
pubmed: 12648934
J Chromatogr A. 2004 Apr 9;1033(1):43-55
pubmed: 15072289
Nat Rev Drug Discov. 2005 Mar;4(3):206-20
pubmed: 15729362
Anal Chem. 2006 Jan 15;78(2):363-71
pubmed: 16408915
Chem Rev. 2007 Jul;107(7):3212-46
pubmed: 17595149
Anal Chem. 2010 Jan 1;82(1):203-10
pubmed: 19961175
J Mass Spectrom. 2010 Jul;45(7):703-14
pubmed: 20623627
Biopharm Drug Dispos. 2010 Oct;31(7):367-95
pubmed: 20830700
Mol Biosyst. 2011 Sep;7(9):2577-88
pubmed: 21761043
J Nat Prod. 2012 Jun 22;75(6):1243-55
pubmed: 22620854
PLoS One. 2013 Sep 04;8(9):e73076
pubmed: 24023812
Anal Chem. 2013 Nov 5;85(21):10330-7
pubmed: 24053138
Nucleic Acids Res. 2014 Jul;42(Web Server issue):W94-9
pubmed: 24895432
Anal Chem. 2014 Oct 7;86(19):9887-94
pubmed: 25180432
Chem Res Toxicol. 1989 Sep-Oct;2(5):316-24
pubmed: 2562425
Anal Chem. 2015 Jul 21;87(14):7373-81
pubmed: 26107650
Proc Natl Acad Sci U S A. 2015 Oct 13;112(41):12580-5
pubmed: 26392543
Nucleic Acids Res. 2016 Jan 4;44(D1):D1202-13
pubmed: 26400175
Nucleic Acids Res. 2016 Jan 4;44(D1):D1214-9
pubmed: 26467479
J Cheminform. 2016 Jan 29;8:3
pubmed: 26834843
Comput Struct Biotechnol J. 2016 Mar 09;14:135-53
pubmed: 27087910
Anal Chem. 2016 Sep 20;88(18):9004-13
pubmed: 27479709
BMC Med. 2016 Nov 4;14(1):177
pubmed: 27814705
Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):13738-13743
pubmed: 27856765
Curr Opin Chem Biol. 2017 Feb;36:1-6
pubmed: 28025165
Anal Chem. 2017 Mar 21;89(6):3300-3309
pubmed: 28240543
J Nat Prod. 2017 Jun 23;80(6):1758-1766
pubmed: 28616931
Anal Chem. 2018 Jan 2;90(1):480-489
pubmed: 29039932
Nucleic Acids Res. 2018 Jan 4;46(D1):D608-D617
pubmed: 29140435
Metabolites. 2018 Jan 17;8(1):null
pubmed: 29342073
Anal Chem. 2018 Mar 6;90(5):3156-3164
pubmed: 29381867
Anal Chem. 2019 Jan 2;91(1):704-742
pubmed: 30453740
Metabolomics. 2019 Mar 14;15(3):45
pubmed: 30874951
J Biochem. 1994 Feb;115(2):362-6
pubmed: 8206887

Auteurs

Luke Whiley (L)

The MRC-NIHR National Phenome Centre and Imperial BRC Clinical Phenotyping Centre , Imperial College London , London , W12 0NN , United Kingdom.
UK Dementia Research Institute , Imperial College London, Hammersmith Hospital , Burlington Danes Building , London , W12 0NN , United Kingdom.

Elena Chekmeneva (E)

The MRC-NIHR National Phenome Centre and Imperial BRC Clinical Phenotyping Centre , Imperial College London , London , W12 0NN , United Kingdom.

David J Berry (DJ)

The MRC-NIHR National Phenome Centre and Imperial BRC Clinical Phenotyping Centre , Imperial College London , London , W12 0NN , United Kingdom.

Beatriz Jiménez (B)

The MRC-NIHR National Phenome Centre and Imperial BRC Clinical Phenotyping Centre , Imperial College London , London , W12 0NN , United Kingdom.

Ada H Y Yuen (AHY)

The MRC-NIHR National Phenome Centre and Imperial BRC Clinical Phenotyping Centre , Imperial College London , London , W12 0NN , United Kingdom.

Ash Salam (A)

The MRC-NIHR National Phenome Centre and Imperial BRC Clinical Phenotyping Centre , Imperial College London , London , W12 0NN , United Kingdom.

Humma Hussain (H)

The MRC-NIHR National Phenome Centre and Imperial BRC Clinical Phenotyping Centre , Imperial College London , London , W12 0NN , United Kingdom.

Matthias Witt (M)

Bruker Daltonik GmbH , MRMS Solutions , 28359 Bremen , Germany.

Zoltan Takats (Z)

The MRC-NIHR National Phenome Centre and Imperial BRC Clinical Phenotyping Centre , Imperial College London , London , W12 0NN , United Kingdom.

Jeremy Nicholson (J)

The MRC-NIHR National Phenome Centre and Imperial BRC Clinical Phenotyping Centre , Imperial College London , London , W12 0NN , United Kingdom.

Matthew R Lewis (MR)

The MRC-NIHR National Phenome Centre and Imperial BRC Clinical Phenotyping Centre , Imperial College London , London , W12 0NN , United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH